Literature DB >> 18440308

Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease.

Lukas Kubala1, Guijing Lu, Stephan Baldus, Lars Berglund, Jason P Eiserich.   

Abstract

BACKGROUND: Plasma and serum levels of myeloperoxidase (MPO), a redox-active hemoprotein released by polymorphonuclear neutrophils (PMN) upon activation, is now recognized as a powerful prognostic determinant of myocardial infarction in patients suffering acute coronary syndromes. However, there is limited information on whether systemic MPO levels are also elevated and of discriminating value in patients with stable coronary artery disease (CAD) representing different ethnic groups.
METHODS: Plasma levels of MPO and traditional CAD risk factors were quantified in African American and Caucasian patients (n=557) undergoing elective coronary angiography.
RESULTS: MPO levels did not differ significantly between patients with or without CAD [421 pM (321, 533) vs. 412 pM (326, 500), p>0.05]. MPO levels were similar across ethnicity and gender, and correlated positively with CRP and fibrinogen levels (r=0.132, p=0.002 and r=0.106, p=0.011, respectively).
CONCLUSION: In conclusion, plasma MPO levels were not elevated in patients with stable CAD, suggesting that systemic release of MPO is not a characteristic feature of asymptomatic CAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440308      PMCID: PMC2474801          DOI: 10.1016/j.cca.2008.04.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  29 in total

1.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.

Authors:  S Sugiyama; Y Okada; G K Sukhova; R Virmani; J W Heinecke; P Libby
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Association between myeloperoxidase levels and risk of coronary artery disease.

Authors:  R Zhang; M L Brennan; X Fu; R J Aviles; G L Pearce; M S Penn; E J Topol; D L Sprecher; S L Hazen
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

3.  Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and Non-Hispanic Caucasians > or =65 years of age living in New York City.

Authors:  Carlos Rodriguez; Ariel Pablos-Méndez; Walter Palmas; Rafael Lantigua; Richard Mayeux; Lars Berglund
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

4.  Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms.

Authors:  A Hoy; D Trégouët; B Leininger-Muller; O Poirier; M Maurice; C Sass; G Siest; L Tiret; S Visvikis
Journal:  Eur J Hum Genet       Date:  2001-10       Impact factor: 4.246

5.  Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Authors:  Furcy Paultre; Catherine H Tuck; Bernadette Boden-Albala; Douglas E Kargman; Elizabeth Todd; Jeffrey Jones; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

6.  High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men.

Authors:  F Paultre; T A Pearson; H F Weil; C H Tuck; M Myerson; J Rubin; C K Francis; H F Marx; E F Philbin; R G Reed; L Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

Review 7.  Myeloperoxidase-generated oxidants and atherosclerosis.

Authors:  E A Podrez; H M Abu-Soud; S L Hazen
Journal:  Free Radic Biol Med       Date:  2000-06-15       Impact factor: 7.376

8.  Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia.

Authors:  Marijn C Meuwese; Mieke D Trip; Sanne van Wissen; Joram N I van Miert; John J P Kastelein; Erik S G Stroes
Journal:  Atherosclerosis       Date:  2007-09-17       Impact factor: 5.162

9.  Widespread coronary inflammation in unstable angina.

Authors:  Antonino Buffon; Luigi M Biasucci; Giovanna Liuzzo; Giuseppe D'Onofrio; Filippo Crea; Attilio Maseri
Journal:  N Engl J Med       Date:  2002-07-04       Impact factor: 91.245

10.  Myeloperoxidase, a leukocyte-derived vascular NO oxidase.

Authors:  Jason P Eiserich; Stephan Baldus; Marie-Luise Brennan; Wenxin Ma; Chunxiang Zhang; Albert Tousson; Laura Castro; Aldons J Lusis; William M Nauseef; C Roger White; Bruce A Freeman
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  13 in total

1.  Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.

Authors:  Farsad Afshinnia; Lixia Zeng; Jaeman Byun; Crystal A Gadegbeku; Maria Chiara Magnone; Carl Whatling; Barbara Valastro; Matthias Kretzler; Subramaniam Pennathur
Journal:  Am J Nephrol       Date:  2017-07-01       Impact factor: 3.754

2.  Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease.

Authors:  W H Wilson Tang; Yuping Wu; Stephen J Nicholls; Stanley L Hazen
Journal:  Clin Chem       Date:  2010-11-08       Impact factor: 8.327

3.  Unraveling mechanisms of toxicant-induced oxidative stress in cardiovascular disease.

Authors:  Tammy R Dugas
Journal:  Curr Opin Toxicol       Date:  2017-10-12

Review 4.  Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?

Authors:  Daniele Pastori; Roberto Carnevale; Pasquale Pignatelli
Journal:  Intern Emerg Med       Date:  2013-09-22       Impact factor: 3.397

5.  Lack of association between plasma myeloperoxidase levels and angiographic severity of coronary artery disease in patients with acute coronary syndrome.

Authors:  Eraldo de Azevedo Lucio; Sandro C Gonçalves; Jorge P Ribeiro; Gilberto L Nunes; Jarbas R de Oliveira; Gustavo N Araujo; Marco V Wainstein
Journal:  Inflamm Res       Date:  2010-09-17       Impact factor: 4.575

6.  Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study.

Authors:  Htet W Khine; John F Teiber; Robert W Haley; Amit Khera; Colby R Ayers; Anand Rohatgi
Journal:  Atherosclerosis       Date:  2017-06-03       Impact factor: 5.162

7.  High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis.

Authors:  Anuradha Vivekanandan-Giri; Jessica L Slocum; Jaeman Byun; Chongren Tang; Robin L Sands; Brenda W Gillespie; Jay W Heinecke; Rajiv Saran; Mariana J Kaplan; Subramaniam Pennathur
Journal:  Ann Rheum Dis       Date:  2013-01-12       Impact factor: 19.103

8.  Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus.

Authors:  Carolyne K Smith; Anuradha Vivekanandan-Giri; Chongren Tang; Jason S Knight; Anna Mathew; Robin L Padilla; Brenda W Gillespie; Carmelo Carmona-Rivera; Xiaodan Liu; Venkataraman Subramanian; Sarfaraz Hasni; Paul R Thompson; Jay W Heinecke; Rajiv Saran; Subramaniam Pennathur; Mariana J Kaplan
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

9.  Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study.

Authors:  Hubert Scharnagl; Marcus E Kleber; Bernd Genser; Sandra Kickmaier; Wilfried Renner; Gisela Weihrauch; Tanja Grammer; Christine Rossmann; Bernhard R Winkelmann; Bernhard O Boehm; Wolfgang Sattler; Winfried März; Ernst Malle
Journal:  Int J Cardiol       Date:  2014-04-03       Impact factor: 4.164

10.  Myeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina.

Authors:  Mehdi Baseri; Ramin Heidari; Behzad Mahaki; Yaghoub Hajizadeh; Amir Momenizadeh; Masoumeh Sadeghi
Journal:  Adv Biomed Res       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.